Lilly ' s Tirzepatide Demonstrates Benefits in Data Presented at the American Diabetes Association ' s ® 79ᵗʰ Scientific Sessions

INDIANAPOLIS, June 8, 2019 /PRNewswire/ -- Results from several studies of Eli Lilly and Company's (NYSE: LLY) investigational dual GIP and GLP-1 receptor agonist (RA), tirzepatide, reinforce its potential in lowering A1C and body weight in...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials